



New CEO Appointed – Dr Paul Mastoridis

Highlights:

- Adherium (ASX:ADR) has announced the appointment of their new Chief Executive Officer (CEO), Dr Paul Mastoridis, following the recent resignation of Rick Legleiter in the role.
- Dr Mastoridis is based in the US and has more than 25 years' experience in the pharmaceutical industry, pioneering and leading digital solutions in asthma and COPD management.
- This key executive appointment coincides with market advancements in the US, which position ADR as the leader of reimbursed, respiratory remote monitoring and data management solutions for patients, physicians, and payers.

Melbourne, Australia – 1 February 2024: Adherium Limited (ASX:ADR) the leader in respiratory digital health technologies, has today announced the appointment of a new CEO, Dr Paul Mastoridis, who is a recognised global pharmaceutical innovator in the asthma and COPD markets.

Dr Mastoridis has more than 25 years' experience in the pharmaceutical industry, pioneering and leading digital solutions in asthma and COPD management. Prior to joining Adherium, he was the Global Medical Head of Respiratory at Novartis. There, Paul and his team developed and patented the first artificial intelligence (AI) technology to differentiate and diagnose asthma from COPD, which delivered superior outcomes to traditional diagnostic methods. They also invented the first smart technology add-on device to Novartis respiratory products to help patients adhere to their medication; a first-generation concept which was subsequently approved and marketed in 18 countries.

In embracing the role of CEO at Adherium, Dr Mastoridis will contribute his expertise to bolster the Company's commercialisation and market penetration strategy for its lead product, the [Hailie® Smartinhaler® system](#) – with an immediate focus on the US. Recent advancements in the reimbursement structure and positive health economic data for respiratory medical devices in the US, position ADR to exceed the Company's near-term commercial ambitions, save millions of dollars to healthcare systems and transform patients' lives.

Dr Mastoridis succeeds outgoing CEO, Rick Legleiter, who announced his resignation from Adherium last month.

Adherium Independent Non-Executive Chair, Mr Lou Panaccio, said: *“On behalf of my fellow directors, and the entire Adherium team, together with our valued shareholders and supporters, I welcome Dr Mastoridis to the position of CEO. In particular, we are celebrating his investment of highly specialised intellectual capital and valuable global networks to our growing business.*

“I would also like to formally thank our outgoing CEO, Rick Legleiter, who has served our Company with focus, professionalism and integrity for the past 3 years – and who has

committed to consulting to the Board and management team for up to 6 months to ensure a smooth transition on all operational fronts to his successor.”

In accepting the new role, Dr Mastoridis shared his vision for Adherium in improving outcomes for people living with respiratory conditions and confidence in market uptake of the Company’s novel [Hailie®](#) technology.

Newly appointed Adherium CEO, Dr Mastoridis, said: *“This is a fantastic opportunity to revolutionise how we manage millions of asthma and COPD patients globally. Adherium is a business with a strong brand portfolio and is a respected leader in patient adherence, remote monitoring and data management solutions for patients, physicians and payers.*

“Our Hailie Smartinhaler technology and patient management system will lead the industry by bringing these innovative devices to patients to help them reduce their exacerbations, hospitalisations, deaths and live better lives.”

Dr Mastoridis will commence in the role on 1 February 2024:

Base pay: US\$350,000.00 per annum

STI: up to 30% of base pay in cash or equity at the discretion of the Board based on annual performance

LTI: 6.6 million ordinary shares to vest in equal tranches over three years from date of commencement

ENDS-

This ASX announcement was approved and authorised for release by the Board of Adherium.

Media Enquiries:

Rudi Michelson

Monsoon Communications

rudim@monsoon.com.au

About Adherium

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium’s clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>